Summary: India’s CRDMO industry is projected to grow from Rs. 60,641 crore (US$ 7 billion) to Rs. 1,21,282 crore (US$ 14 billion) by 2028 at a 14% CAGR, driven by pharmaceutical outsourcing, regulatory support, and supply chain shifts. The US Biosecure Act could boost growth further, pushing revenues to Rs. 1,90,586 crore (US$ 22 billion) by 2030.

The Asia-Pacific pharmaceutical CDMO sector, valued at Rs. 4,33,150 crore (US$ 50 billion) in 2023, is growing due to cost advantages, outsourcing trends, and geopolitical risks. India’s CDMOs offer 30-40% lower costs than Western firms, strong regulatory approvals, and expertise in APIs, HPAPIs, and specialty chemicals, positioning India for sustained long-term growth.

Source: IBEF 

Disclaimer: The information on this website comes from the India Brand Equity Foundation (IBEF), a reliable source for thorough insights into numerous areas of the Indian economy. While we aim to offer accurate and up-to-date information, the views, opinions, and analyses stated herein are solely those of the authors and contributors and do not necessarily represent IBEF's official stance or position. Readers should check information from credible sources and use their own discretion when relying on content provided on this site. We assume no responsibility or liability for the supplied content, including its accuracy, completeness, and usefulness.